Janssen Research & Development, LLC
janssen.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
926
Active
166
Phase 3
210
Total enrollment
4,903,103
Pipeline matrix
Showing 40 of 185 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Guselkumab | — | 36 | |||||
| Apalutamide | — | — | 13 | ||||
| Cilta-cel | — | — | — | 6 | |||
| Androgen-deprivation Therapy | — | — | — | — | 2 | ||
| Amivantamab | — | — | 20 | ||||
| Teclistamab | — | — | 16 | ||||
| Dexamethasone | — | — | — | 29 | |||
| Daratumumab | — | — | 35 | ||||
| Talquetamab | — | — | 15 | ||||
| Nipocalimab | — | — | 21 | ||||
| Bortezomib | — | — | — | 18 | |||
| Lazertinib | — | — | — | 16 | |||
| Pomalidomide | — | — | — | — | 11 | ||
| Lenalidomide | — | — | — | 18 | |||
| Carboplatin | — | — | — | 10 | |||
| Prednisone | — | — | — | 25 | |||
| Cetrelimab | — | — | — | 8 | |||
| Pemetrexed | — | — | — | 6 | |||
| JNJ-77242113 | — | — | — | 10 | |||
| JNJ-79635322 | — | — | — | 5 | |||
| Venetoclax | — | — | — | 5 | |||
| Cyclophosphamide | — | — | — | — | 8 | ||
| Icotrokinra | — | — | — | — | — | 4 | |
| Bleximenib | — | — | — | 4 | |||
| Gemcitabine | — | — | — | — | — | 4 | |
| Pasritamig | — | — | — | — | 4 | ||
| JNJ-78934804 | — | — | — | — | 4 | ||
| Abiraterone acetate | — | — | 21 | ||||
| Ustekinumab | — | 18 | |||||
| TAR-200 | — | — | 7 | ||||
| Ibrutinib | — | — | 24 | ||||
| Erdafitinib | — | — | — | 9 | |||
| Guselkumab Dose 1 | — | — | — | — | 6 | ||
| Guselkumab Dose 2 | — | — | — | — | 6 | ||
| Carfilzomib | — | — | — | 5 | |||
| Niraparib | — | — | — | 5 | |||
| Guselkumab Dose 3 | — | — | — | — | 4 | ||
| Docetaxel | — | — | — | 4 | |||
| Fludarabine | — | — | — | 4 | |||
| Cisplatin | — | — | — | — | 3 |
145 more active programs hidden
Next readouts
- 2019-07-09
- 2021-02-26
- 2021-08-31
- 2021-10-08
- 2021-10-15
- 2021-11-09
- 2022-07-07
- 2022-09-15
- 2022-09-30
- 2023-05-03
Top conditions
- Healthy232
- Multiple Myeloma55
- Depressive Disorder, Major30
- Diabetes Mellitus, Type 226
- Colitis, Ulcerative20
- Prostatic Neoplasms19
- Carcinoma, Non-Small-Cell Lung17
- Arthritis, Psoriatic17
Frequently asked questions about Janssen Research & Development, LLC
- How many clinical trials does Janssen Research & Development, LLC have on ClinicalTrials.gov?
- Janssen Research & Development, LLC is listed as the lead sponsor on 926 clinical trials in ClinicalTrials.gov, 166 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Janssen Research & Development, LLC's trials are in Phase 3?
- 210 of Janssen Research & Development, LLC's trials are in Phase 3, spread across 185 active drug programs.
- What therapeutic areas does Janssen Research & Development, LLC focus on?
- Janssen Research & Development, LLC's most-studied conditions on ClinicalTrials.gov are Healthy, Multiple Myeloma, Depressive Disorder, Major, Diabetes Mellitus, Type 2, Colitis, Ulcerative.
- When are Janssen Research & Development, LLC's next clinical trial readouts?
- Janssen Research & Development, LLC has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer”, expected around 2019-07-09.